Volume 56, Issue 1 pp. 41-48
BLOOD COMPONENTS

Effects of riboflavin and amotosalen photoactivation systems for pathogen inactivation of fresh-frozen plasma on fibrin clot structure

Thomas Hubbard

Thomas Hubbard

Theme Thrombosis, Division of Cardiovascular and Diabetes Research, Multidisciplinary Cardiovascular Research Centre and Leeds Institute for Genetics, Health and Therapeutics, Faculty of Medicine and Health, University of Leeds, Leeds

Search for more papers by this author
Lucy Backholer

Lucy Backholer

NHS Blood & Transplant, Cambridge, UK

Search for more papers by this author
Michael Wiltshire

Michael Wiltshire

NHS Blood & Transplant, Cambridge, UK

Search for more papers by this author
Rebecca Cardigan

Rebecca Cardigan

NHS Blood & Transplant, Cambridge, UK

Search for more papers by this author
Robert A.S. Ariëns

Corresponding Author

Robert A.S. Ariëns

Theme Thrombosis, Division of Cardiovascular and Diabetes Research, Multidisciplinary Cardiovascular Research Centre and Leeds Institute for Genetics, Health and Therapeutics, Faculty of Medicine and Health, University of Leeds, Leeds

Address reprint requests to: Robert Ariëns, Theme Thrombosis LIGHT Laboratories, Clarendon Way, University of Leeds, Leeds, UK; e-mail: [email protected].Search for more papers by this author
First published: 10 September 2015
Citations: 10

Abstract

BACKGROUND

Fresh-frozen plasma (FFP) transfusion carries a risk of viral transmission from donor to recipient. Riboflavin (Mirasol) and amotosalen (Intercept) are two pathogen inactivation (PI) methods that may enhance the safety of FFP for transfusion. Our study investigated the effects of Mirasol and Intercept treatment on fibrin formation and clot structure.

STUDY DESIGN AND METHODS

FFP underwent either Mirasol or Intercept treatment, and aliquots were taken before addition of the compound, before illumination (after addition of compound only), and after treatment (addition of compound plus illumination). All samples underwent turbidimetric analysis, lysis analysis, assessment of clot permeation, and analysis by laser scanning confocal microscopy.

RESULTS

After treatment, there was a decrease in optical density of the fibrin network for Mirasol and Intercept, lag time to fibrin formation was prolonged for Mirasol and lysis time for Intercept, clot permeability was significantly decreased, and clot density was increased for both.

CONCLUSIONS

Our study shows that plasma treated with Mirasol and Intercept produces denser clots consisting of thinner fibers and warrants further studies to evaluate the clinical significance of these structural changes in fibrin clot formation.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.